Trial reportDigestive diseases and sciences2004
A pilot study of etanercept in the treatment of primary sclerosing cholangitis.
Trial report in Digestive diseases and sciences, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- European S2k Guideline on Chronic PruritusActa dermato-venereologica · 2025Guideline
- Clinical guidelines for primary sclerosing cholangitis 2017.Journal of gastroenterology · 2018Guideline
- The Many Faces of Primary Sclerosing Cholangitis: Controversy Abounds.Digestive diseases and sciences · 2023Review
- Colectomy in patients with ulcerative colitis is not associated to future diagnosis of primary sclerosing cholangitis.United European gastroenterology journal · 2023Article
- The microbiota and the gut-liver axis in primary sclerosing cholangitis.Nature reviews. Gastroenterology & hepatology · 2023Review
- Hepatobiliary manifestations following two-stages elective laparoscopic restorative proctocolectomy for patients with ulcerative colitis: A prospective observational study.World journal of gastrointestinal surgery · 2023Article
- Review
- Treatment of primary sclerosing cholangitis in children.World journal of hepatology · 2019Review
- The Use of Biologics in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.Current hepatology reports · 2019Review
- Primary Sclerosing Cholangitis, Part 1: Epidemiology, Etiopathogenesis, Clinical Features, and Treatment.Gastroenterology & hepatology · 2018Article
- Cholestatic liver diseases: new targets, new therapies.Therapeutic advances in gastroenterology · 2018Review
- Pathogenesis and clinical spectrum of primary sclerosing cholangitis.World journal of gastroenterology · 2017Review
- Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis.The Cochrane database of systematic reviews · 2017Review
- Update on pharmacotherapies for cholestatic liver disease.Hepatology communications · 2017Review
- Primary sclerosing cholangitis: diagnostic and management challenges.Clinical and experimental gastroenterology · 2017Review
- Novel treatments in primary sclerosing cholangitis.Clinical liver disease · 2016Review
- A review of the medical treatment of primary sclerosing cholangitis in the 21st century.Therapeutic advances in chronic disease · 2016Review
- Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management.Gastroenterology · 2013Review
- Steroid-refractory ulcerative colitis and associated primary sclerosing cholangitis treated with infliximab.World journal of gastroenterology · 2013Article
- Management of primary sclerosing cholangitis: conventions and controversies.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is no effective medical treatment for primary sclerosing cholangitis (PSC), a chronic cholestatic liver disease that usually progresses to cirrhosis and liver failure. The aim of this study was to determine the safety and efficacy of etanercept, an inhibitor of tumor necrosis factor, in the treatment of PSC. Ten patients with clinically active PSC were studied. All had elevated serum alkaline phosphatase levels, cholangiograms that were diagnostic of PSC, and liver histology consistent with PSC. Five patients had elevated serum bilirubin levels, five had pruritus, eight had failed to respond to ursodiol and/or methotrexate, and six had rapidly recurring dominant bile duct strictures. Patients were to receive etanercept, 25 mg subcutaneously twice weekly, for 6 months if there were no side effects and for 1 year if there was evidence of efficacy after 6 months. Biochemical tests of liver function did not improve in any patient. Mean serum bilirubin levels increased significantly, from 2.0 to 3.6 mg/dl (P = 0.026). Two of the five patients with pruritus had resolution of pruritus during treatment with etanercept, recurrence when etanercept was stopped, and resolution when it was restarted, although there was little change in liver enzymes or bilirubin levels. There was no decrease in the rate of stricture formation and there were no side effects. Etanercept, at the dosage used, was well tolerated but not effective in the treatment of PSC. It may be helpful in treating pruritus due to cholestasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.